CY1116190T1 - Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην - Google Patents
Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτηνInfo
- Publication number
- CY1116190T1 CY1116190T1 CY20151100059T CY151100059T CY1116190T1 CY 1116190 T1 CY1116190 T1 CY 1116190T1 CY 20151100059 T CY20151100059 T CY 20151100059T CY 151100059 T CY151100059 T CY 151100059T CY 1116190 T1 CY1116190 T1 CY 1116190T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical composition
- intermediative
- religious
- activated
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Αποκαλύπτεται οπτικά ενεργό παράγωγο 4-φαινυλοθειαζολίου που διαθέτει δραστικότητα αγωνιστή υποδοχέα θρομβοποιητίνης. Επίσης αποκαλύπτεται φαρμακευτική σύνθεση που περιέχει τέτοια ένωση ως δραστικό συστατικό, η οποία δημιουργεί από του στόματος χορηγήσιμο παράγοντα ελέγχου παραγωγής αιμοπεταλίων. Πιο συγκεκριμένα αποκαλύπτεται φαρμακευτική σύνθεση που περιέχει, ως δραστικό συστατικό, οπτικά ενεργή ένωση αναπαριστώμενη από τον τύπο παρακάτω, ένα φαρμακευτικά αποδεκτό άλας αυτής, ή ένα επιδιαλυτωμένο σύμπλεγμα οιουδήποτε εξ αυτών. (Στον τύπο, η R1 αναπαριστά άτομο αλογόνου ή ομάδα C1-C3 αλκυλοξυ· η R2 αναπαριστά ομάδα C1-C8 αλκυλίου· η R3 αναπαριστά ομάδα C1-C8 αλκυλίου· οι R4 και R5 αναπαριστούν ανεξαρτήτως άτομο φθορίου ή άτομο χλωρίου· η R6 αναπαριστά ομάδα C1-C3 αλκυλίου ή ομάδα C1-C3 αλκυλοξυ· και * αναπαριστά ασύμμετρο άτομο άνθρακα).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007198590 | 2007-07-31 | ||
| EP08791776.1A EP2184279B1 (en) | 2007-07-31 | 2008-07-29 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116190T1 true CY1116190T1 (el) | 2017-02-08 |
Family
ID=40304328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100059T CY1116190T1 (el) | 2007-07-31 | 2015-01-21 | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8530668B2 (el) |
| EP (1) | EP2184279B1 (el) |
| JP (1) | JP5164181B2 (el) |
| KR (1) | KR20100027243A (el) |
| CN (4) | CN101809008B (el) |
| AU (1) | AU2008283357B2 (el) |
| BR (1) | BRPI0814891A2 (el) |
| CA (1) | CA2694567C (el) |
| CY (1) | CY1116190T1 (el) |
| DK (1) | DK2184279T3 (el) |
| ES (1) | ES2528196T3 (el) |
| FR (1) | FR19C1043I2 (el) |
| HR (1) | HRP20150062T1 (el) |
| MX (1) | MX2010001082A (el) |
| NL (1) | NL300998I2 (el) |
| PL (1) | PL2184279T3 (el) |
| PT (1) | PT2184279E (el) |
| RU (1) | RU2476429C2 (el) |
| SI (1) | SI2184279T1 (el) |
| TW (1) | TWI422371B (el) |
| WO (1) | WO2009017098A1 (el) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI564008B (zh) * | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
| JP6202620B2 (ja) * | 2012-06-29 | 2017-09-27 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有する化合物を含有する医薬組成物 |
| US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| WO2015093586A1 (ja) * | 2013-12-20 | 2015-06-25 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法 |
| CN105412930A (zh) * | 2015-08-07 | 2016-03-23 | 军事医学科学院华南干细胞与再生医学研究中心 | 血小板生成素受体激动剂在促进造血干细胞归巢中的用途 |
| JP6168579B1 (ja) * | 2016-02-12 | 2017-07-26 | 塩野義製薬株式会社 | 重度の肝機能障害のある患者のためのルストロンボパグを含有する血小板産生促進剤 |
| CN106083759B (zh) * | 2016-06-15 | 2022-02-15 | 上海丸全化学科技有限公司 | 一种芦曲泊帕的全新合成工艺 |
| US20190315771A1 (en) | 2016-09-08 | 2019-10-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Novel 2-acylaminothiazole derivative and preparation method therefor and use thereof |
| CN106565625B (zh) * | 2016-11-04 | 2018-01-30 | 杭州励德生物科技有限公司 | 一种抗血小板减少症新药Lusutrombopag中间体的制备方法 |
| CN109311831B (zh) * | 2017-02-14 | 2021-07-09 | 四川科伦药物研究院有限公司 | 4-苯基噻唑衍生物的晶型及其制备方法 |
| CN109970678B (zh) * | 2017-12-28 | 2024-03-08 | 四川科伦药物研究院有限公司 | 4-苯基噻唑衍生物无定形及其制备方法和用途 |
| EP3808736B1 (en) * | 2018-06-08 | 2023-08-09 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Crystal form of 4-phenylthiazole derivative and preparation method thereof |
| WO2020116447A1 (ja) * | 2018-12-04 | 2020-06-11 | 塩野義製薬株式会社 | 難溶性薬物の固体分散体 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0885242T3 (da) * | 1995-06-07 | 2008-07-14 | Glaxo Group Ltd | Peptider og forbindelser, der binder til en trombopoietinreceptor |
| JPH1072492A (ja) | 1996-09-02 | 1998-03-17 | Hokuriku Seiyaku Co Ltd | ペプチド化合物 |
| JPH10287634A (ja) | 1997-04-11 | 1998-10-27 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体 |
| JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | １，４−ベンゾジアゼピン誘導体及びその用途 |
| JPH11152276A (ja) | 1997-11-20 | 1999-06-08 | Hokuriku Seiyaku Co Ltd | ベンゾジアゼピン誘導体 |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| GC0000177A (en) * | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| EP1207155A4 (en) | 1999-07-26 | 2005-01-12 | Shionogi & Co | DRUG COMPOSITIONS HAVING AGONIST THROMBOPOIETINE ACTIVITY |
| TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| EP1361220A4 (en) | 2001-01-26 | 2005-09-07 | Shionogi & Co | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM |
| CA2435143A1 (en) | 2001-01-26 | 2002-08-01 | Shionogi & Co., Ltd. | Halogen compounds having thrombopoietin receptor agonism |
| US20040077697A1 (en) | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
| ES2416304T3 (es) | 2002-01-18 | 2013-07-31 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
| JP4317818B2 (ja) | 2002-09-30 | 2009-08-19 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体の新規な塩 |
| US6737382B1 (en) * | 2002-10-23 | 2004-05-18 | Nippon Soda Co. Ltd. | Insecticidal aminothiazole derivatives |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| JP4324791B2 (ja) | 2003-07-17 | 2009-09-02 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| WO2005014561A1 (ja) * | 2003-08-12 | 2005-02-17 | Shionogi & Co., Ltd. | トロンボポエチン受容体アゴニスト作用を有する化合物 |
| EP1664006A2 (en) * | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| JP4665769B2 (ja) | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| JP4774995B2 (ja) | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| WO2007004038A1 (en) | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
| US8515798B2 (en) | 2005-09-27 | 2013-08-20 | Accenture Global Services Gmbh | Closed-loop supply chain in the paper packaging sector |
| AU2006313491B2 (en) | 2005-11-08 | 2011-01-06 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
-
2008
- 2008-07-29 AU AU2008283357A patent/AU2008283357B2/en active Active
- 2008-07-29 PL PL08791776T patent/PL2184279T3/pl unknown
- 2008-07-29 EP EP08791776.1A patent/EP2184279B1/en active Active
- 2008-07-29 CA CA2694567A patent/CA2694567C/en active Active
- 2008-07-29 CN CN2008801104301A patent/CN101809008B/zh active Active
- 2008-07-29 CN CN201310356204.4A patent/CN103396313B/zh active Active
- 2008-07-29 CN CN201310356507.6A patent/CN103450110B/zh active Active
- 2008-07-29 RU RU2010107169/04A patent/RU2476429C2/ru active
- 2008-07-29 JP JP2009525398A patent/JP5164181B2/ja active Active
- 2008-07-29 BR BRPI0814891-0A patent/BRPI0814891A2/pt not_active IP Right Cessation
- 2008-07-29 ES ES08791776.1T patent/ES2528196T3/es active Active
- 2008-07-29 KR KR1020107002144A patent/KR20100027243A/ko active Search and Examination
- 2008-07-29 CN CN2013103563691A patent/CN103393678A/zh active Pending
- 2008-07-29 SI SI200831361T patent/SI2184279T1/sl unknown
- 2008-07-29 WO PCT/JP2008/063541 patent/WO2009017098A1/ja active Application Filing
- 2008-07-29 MX MX2010001082A patent/MX2010001082A/es active IP Right Grant
- 2008-07-29 DK DK08791776.1T patent/DK2184279T3/en active
- 2008-07-29 US US12/671,476 patent/US8530668B2/en active Active
- 2008-07-29 PT PT87917761T patent/PT2184279E/pt unknown
- 2008-07-30 TW TW097128751A patent/TWI422371B/zh active
-
2013
- 2013-02-13 US US13/766,752 patent/US8889722B2/en active Active
-
2015
- 2015-01-19 HR HRP20150062AT patent/HRP20150062T1/hr unknown
- 2015-01-21 CY CY20151100059T patent/CY1116190T1/el unknown
-
2019
- 2019-06-27 NL NL300998C patent/NL300998I2/nl unknown
- 2019-06-28 FR FR19C1043C patent/FR19C1043I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116190T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην | |
| CY1122761T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
| CY1119176T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| RS51137B (sr) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| CY1112911T1 (el) | Θεραπευτικος παραγοντας ηπατικης νοσου, που περιεχει παραγωγο 2-αμινο-1,3-προπανοδιολης ως δραστικο συστατικο | |
| DE602004016127D1 (de) | Antagonisten der opioidrezeptoren | |
| CY1109787T1 (el) | Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| UY30310A1 (es) | Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| TW200633984A (en) | Amide compounds and activators of thrombopoietin receptor | |
| DE602006018713D1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
| PA8568101A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso | |
| UY27979A1 (es) | Indoles sustituidos en posición 2,4 | |
| UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones | |
| WO2022261240A3 (en) | Dimethoxyphenylalkylamine activators of serotonin receptors | |
| TW200633997A (en) | Substituted heterocyclic compounds and thrombopoietin receptor activators | |
| JP2007507467A5 (el) | ||
| ATE448220T1 (de) | Heterocyclische modulatoren für den gaba-alpha- subtyp-selektiven rezeptor | |
| RU2003113145A (ru) | Замещенные 5r1, 6r2-1, 3,4-тиадиазин-2, амины и содержащие их фармацевтические композиции в качестве фармакологически активных средств, обладающих антикоагулятным и антиагрегатным действием | |
| NO20090741L (no) | Imino-imidazo-pyridinderivater med antitrombotisk aktivitet | |
| BRPI0812978A2 (pt) | Compostos de benzenosulfonamida adequados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3 |